{"provider":{"host":"clinicalintelpulse.theaslangroupllc.com","name":"ClinicalIntelPulse","score":64.5,"live":true,"checkedAt":"2026-10-27T18:57:10.073Z","uptime72h":100,"lastCheck":{"httpStatus":402,"ms":375,"note":"valid x402 v2 terms"},"endpoints":15,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"cheapestUsd":"0.02","income7dUsd":"5.48","payers7d":17,"transfers7d":52,"payoutAddressShared":true,"claimed":false,"page":"https://logicnodes.io/observatory/p/clinicalintelpulse.theaslangroupllc.com"},"endpoints":[{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-check","method":"GET","priceMicroUsd":20000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"ClinicalTrials.gov lookup, deterministic. Answers \"what is the status of NCT02142738\", \"recruiting phase-3 melanoma trials\", \"Pfizer trial pipeline\". Single trial by NCT id (status, phase, sponsor, enrollment, dates, countries) or search by condition/sponsor with phase and status filters. Typed records straight off the official v2 API — no LLM, no key, public domain."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/drug-check","method":"GET","priceMicroUsd":100000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"What is this medication? Plain-language explainer for any prescription or OTC drug from its FDA-approved label — what it treats, how to take it, boxed warnings, who should not take it, common and serious side effects, pregnancy notes. For patient, caregiver, pharmacy, and health-assistant agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/patient-finder","method":"GET","priceMicroUsd":100000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Recruiting clinical trial finder for a disease or diagnosis — actively recruiting trials with plain-language summaries, eligibility (who can/cannot join), country filter, contacts and how to apply, across 400,000+ ClinicalTrials.gov studies worldwide. For patient-advocacy and provider agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/recall-check","method":"GET","priceMicroUsd":100000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Is my medication recalled? Checks the FDA enforcement databases (drug AND food — infant formula and supplements are filed under food) for active and past recalls, explains the recall class (I/II/III) in plain language, and lays out what to do. For patient, caregiver, pharmacy, and health-assistant agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/trial-brief","method":"GET","priceMicroUsd":100000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials","method":"GET","priceMicroUsd":150000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan","method":"GET","priceMicroUsd":150000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis","method":"GET","priceMicroUsd":200000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map","method":"GET","priceMicroUsd":200000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel","method":"GET","priceMicroUsd":200000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook","method":"GET","priceMicroUsd":250000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal-lite","method":"GET","priceMicroUsd":250000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likely acquirers and timing signals."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape-lite","method":"GET","priceMicroUsd":250000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Deterministic preview of the disease pipeline landscape — Phase 2/3 trial counts, sponsor rollup, trial-status breakdown and a sample of trials straight off ClinicalTrials.gov. No LLM synthesis. For agents with small per-call budgets; upgrade to disease-landscape for approved drugs, mechanism gaps, PDUFA calendar, deal activity and an opportunity score."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal","method":"GET","priceMicroUsd":350000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents."},{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape","method":"GET","priceMicroUsd":350000,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"description":"Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents."}]}